The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Treatment options for patients with triple-class refractory myeloma: the value of immunotherapy
Michele Cavo, MD, PhD, Bologna University School of Medicine, Bologna, Italy, discusses the value of immunotherapeutic agents, including CAR-T cells and bispecific antibodies, in the treatment of patients with triple-class refractory multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
